Please login to the form below
loss of exclusivity
This page shows the latest loss of exclusivity news and features for those working in and with pharma, biotech and healthcare.
Eli Lilly shares adjusted financial guidance for 2023
its loss of patent exclusivity and no expected COVID-19 antibody revenue. ... Lilly also took into account the continued negative affect of foreign exchange rates.
Latest news
-
Gilead sales rise by 13%, buoyed by anti-COVID-19 drug Veklury
Without the Veklury bump, total product sales decreased by 3% to $5.4bn for the third quarter, primarily due to the loss of exclusivity of HIV combination therapies Truvada (emtricitabine/tenofovir ... The dynamics of the HIV treatment market further
-
Merck spin-off Organon sees share price jump at Q2 results
Organon also announced a quarterly dividend of $0.28 for each share of common stock. ... Finally, revenue for its established brands – a broad portfolio of well-known medicines generally beyond market exclusivity – were down by 4%, which the company
-
Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit
However, total product sales excluding Veklury dropped by 11% to $4.9bn compared to Q1 2020, due to the loss of exclusivity of its HIV drugs Truvada, tenofovir disoproxil fumarate and ... Gilead added that sales of Veklury would also continue to be
-
New data keeps AbbVie’s star pipeline therapies on track
when it came to keeping patients in work without loss of productivity caused by the skin disorder. ... The prospects for risankizumab and upadacitinib matter for AbbVie because it’s well-recognised that the loss of exclusivity for Humira after 2022 in
-
Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab's OX40 candidate
Biosimilar companies are now gearing up to pounce on AbbVie’s inflammation blockbuster Humira (adalimumab) when it loses its patent exclusivity across Europe on 16 October. ... As the potential savings are so great, NHS England’s Commercial Medicines
More from news
Approximately 0 fully matching, plus 56 partially matching documents found.
Latest Intelligence
-
Back to the future
The loss of exclusivity for Lipitor continued to have a major impact, but alongside this, a further 24 of its therapies suffered a drop in sales. ... in an attempt to mirror the success of Roche and its Genentech subsidiary.”.
-
Who tops the pharma list?
Loss of exclusivity on some of its leading brands - not least Lipitor - contributed to an overall dip in revenue of more than $6.5bn from 2011. ... In fact, patent expiry was an industry-wide epidemic in 2011/12, with loss of exclusivity plaguing many of
-
Interview: Trevor Smith, Takeda
Major products were about to lose, or had just lost, their patent exclusivity.”. ... For Nycomed this meant loss of exclusivity (LOE) on its blockbuster gastroinestinal drug pantoprazole and the consequent need to reorganise its business.
-
The true meaning of market access?
Appropriate patients. Payers want predictability of patient outcomes and certainty of budget impact. ... Market access is everyone's responsibility throughout the life of the medicine from early phase R&D right through to loss of exclusivity.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Three strategies for managing loss of exclusivity successfully
4. It’s no wonder “loss of exclusivity (LOE)” or “the patent cliff” is an ominous prospect for drug manufacturers – shrouded in the threat of job losses and falling share prices. ... Loss of exclusivity (LOE) is a natural milestone in a
-
Publicis Health UK Launches Unique Agency Offering for Clients Under Langland
As a Publicis Health company, Langland has first-hand experience of the value of working as one team. ... Simplifying client access to talent builds on Publicis Groupe’s philosophy: The Power of One - ensuring continuous access to expertise and
-
Envision Pharma Group acquires Two Labs to advance its position as a global strategic partner to pharma and create a unique and unrivaled launch excellence offering
Since its inception in 2003, Two Labs has led 215+ new product launches and more than 300+ in-market projects from pre-launch to loss of exclusivity. ... For further information:. Jessica Krauser. VP of Marketing. Two Labs. Email:
-
Mergers and acquisitions: agents for change
pharmaceutical industry probably experiences more of this type of activity than most others. ... Whether you’re dealing with a merger, a disruptive new competitor, loss of exclusivity, or preparing for launch, contact Bedrock to discuss navigating
-
Three strategies for managing loss of exclusivity successfully
It’s no wonder “loss of exclusivity (LOE)” or “the patent cliff” is an ominous prospect for drug manufacturers – shrouded in the threat of job losses and falling share prices. ... Loss of exclusivity (LOE) is a natural milestone in a drug’s
More from PMHub
Approximately 1 fully matching, plus 9 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- LEO Pharma enters clinical trial partnership with ICON
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- UCB's bimekizumab shows continued improvement in hidradenitis suppurativa patients
- The Considered appoints Bam Zahraie as chief experience officer
- The impact of pharma congresses on HCPs – virtual and in person
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- A relentless commitment to neuroscience
- Alzheon says data backs potential of Alzheimer's candidate
- BMS will not launch cancer drug Opdualag in Germany due to pricing pressures
- Regeneron’s application for Eylea in retinopathy of prematurity accepted for FDA priority review
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
